Haemonetics (HAE) Common Equity (2010 - 2026)

Haemonetics' Common Equity history runs 17 years deep, the most recent figure standing at $796.3 million for Q1 2026.

• In Q1 2026, Common Equity fell 2.99% year-over-year to $796.3 million; the TTM figure through Mar 2026 stood at $796.3 million (down 2.99% YoY), while the FY2026 annual figure was $796.3 million, down 2.99% from the prior year.
• Common Equity was $796.3 million for Q1 2026 at Haemonetics, down from $911.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $960.0 million in Q1 2024 to a low of $729.0 million in Q4 2022.
• Historically, Common Equity has averaged $843.7 million across 5 years, with a median of $856.9 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Common Equity gained 22.59% in 2023, then slipped 14.49% in 2025.
• A 5-year view of Common Equity shows it stood at $776.0 million in 2022, then advanced by 21.57% to $943.3 million in 2023, then slipped by 3.86% to $906.9 million in 2024, then rose by 0.51% to $911.5 million in 2025, then fell by 12.63% to $796.3 million in 2026.
• The last three Common Equity figures came in at $796.3 million (Q1 2026), $911.5 million (Q4 2025), and $849.2 million (Q3 2025), per Business Quant data.